Assess whether to resubmit, meet, or pause the program after a boxed-warning

SITUATION An RWE group proposing a post-marketing study instead of a new RCT cannot treat a boxed-warning proposal from the review division as incidental context on disproportionate reporting signal workbook. Labeling negotiator must close to resubmit, meet, or from that extract under Pharma & Life Sciences / Clinical and Evidence Strategy.

DECISION Labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT must choose To resubmit, meet, / Pause the program using disproportionate reporting signal workbook after a boxed-warning proposal from the review division.

HYPOTHESES TO TEST 1. Disproportionate reporting signal workbook reads as To resubmit, meet, once a boxed-warning proposal from the review division is lined up to the same Pharma & Life Sciences population. 2. Disproportionate reporting signal workbook is closer to Pause the program after a boxed-warning proposal from the review division; To resubmit, meet, would over-claim this Clinical and Evidence Strategy extract. 3. A dual reading is still live in disproportionate reporting signal workbook for labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT. 4. Disproportionate reporting signal workbook is missing the fact labeling negotiator needs after a boxed-warning proposal from the review division; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Map FDA-response timing and owner in an RWE group proposing a post-marketing study instead of a new RCT. 2. Trace CMC, labeling, or pharmacovigilance facts in disproportionate reporting signal workbook after a boxed-warning proposal from the review division. 3. Separate an isolated adverse event from a systemic quality issue. 4. For this Pharma & Life Sciences Clinical and Evidence Strategy file, read disproportionate reporting signal workbook against a boxed-warning proposal from the review division and write the one fact that would move to resubmit, meet, or for labeling negotiator.

RECOMMENDATION Choose To resubmit, meet, / Pause the program on this Pharma & Life Sciences / Clinical and Evidence Strategy packet (disproportionate reporting signal workbook after a boxed-warning proposal from the review division). Lead with the Pharma & Life Sciences option disproportionate reporting signal workbook can support after a boxed-warning proposal from the review division, then the two facts that force it, then the Monday action for labeling negotiator in an RWE group proposing a post-marketing study instead of a new RCT.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to resubmit, meet, or, then the evidence in disproportionate reporting signal workbook, then the action for labeling negotiator - Hypothesis scorecard against disproportionate reporting signal workbook: supported / rejected / untestable - Clinical and Evidence Strategy finding in disproportionate reporting signal workbook that a second reviewer can re-perform - Missing page in disproportionate reporting signal workbook after a boxed-warning proposal from the review division, if any